Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

• Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity [ Time Frame: 72 days ] [ Designated as safety issue: No ]
• Maximum measured concentration of the analyte in plasma [ Time Frame: 72 days ] [ Designated as safety issue: No ]

• Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point [ Time Frame: 72 days ] [ Designated as safety issue: No ]
• Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 14 [ Time Frame: 72 days ] [ Designated as safety issue: No ]
• Terminal phase half life [ Time Frame: 72 days ] [ Designated as safety issue: No ]
• Apparent clearance of the analyte in the plasma after extravascular administration [ Time Frame: 72 days ] [ Designated as safety issue: No ]

This trial will investigate the pharmacokinetics, safety and tolerability of BI 695501 and to establish pharmacokinetic equivalence of BI 695501 to adalimumab.

• Drug: adalimumab
  40mg adalimumab single s.c. injection
• Drug: BI695501
  BI 695501 single s.c injection

• Experimental: BI 695501
  Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
  Intervention: Drug: BI695501
• Active Comparator: adalimumab - US
  Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
  Intervention: Drug: adalimumab
• Active Comparator: adalimumab - EU
  Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
  Intervention: Drug: adalimumab

Inclusion criteria:

1. Healthy males
2. Body mass index (BMI) =18.5 to =29.9 kg/m2

Exclusion criteria:

1. Any clinically relevant abnormal finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance
2. Any evidence of a clinically relevant previous or concomitant disease as judged by the investigator.
3. Chronic or relevant acute infections. A negative result for Human Immunodeficiency Virus, Hepatitis B and Hepatitis C testing is required for participation.
4. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
5. Intake of prescribed or over-the-counter drugs with a long half-life (>24 hours) within at least one month or less than 5 half-lives of the respective drug prior to administration or during the trial
6. Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
7. Inability to refrain from smoking during days of confinement at the study center
8. Alcohol abuse (average more than 30 g/day)
9. Current drug abuse